ClinicalTrials.gg
CompletedNCT00312208Updated Dec 30, 2013Results posted

Docetaxel in Breast Cancer

A Phase 3 interventional study of docetaxel, doxorubicin, cyclophosphamide and Docetaxel,doxorubicin, cyclophosphamide in Breast Cancer, sponsored by Sanofi. Completed at 37 sites in 37 countries. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-12-30.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,299
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.

Enrollment
5th of 248
3,299 · median 68
Started
2001
with 12 others
Phase 3
51 of 264
5 open now
Registered
106th of 264
by date
Lead sponsor
6 of 264
Sanofi

Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 5th largest by enrollment of the 248 interventional ones that give a count, is one of 13 that started in 2001, is one of 51 in phase 3, and was the 106th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 264 studies testing docetaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

Primary objective :

  • To compare disease-free survival after treatment with docetaxel in combination with doxorubicin and cyclophosphamide to doxorubicin and cyclophosphamide followed by docetaxel in operable adjuvant breast cancer HER2neu negative patients with positive axillary lymph nodes.

Secondary objectives :

  • To compare toxicity and quality of life between the 2 above-mentioned arms.
  • To evaluate pathologic and molecular markers for predicting efficacy.
03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven breast cancer. Interval between definitive surgery that includes axillary lymph node dissection and registration is less than or equal to 60 days. A central pathology review may be performed post randomization for confirmation of diagnosis and molecular studies.
  • Definitive surgical treatment must be either mastectomy, or breast conserving surgery with axillary lymph node dissection for operable breast cancer (T1-3, Clinical N0-1, M0). Margins of resected specimen from definitive surgery must be histologically free of invasive adenocarcinoma and Ductal Carcinoma In Situ (DCIS). Lobular carcinoma in-situ does not count as a positive margin.
  • Histologic examination of the tumor: Invasive adenocarcinoma with at least one axillary lymph node (pN1) showing evidence of tumor among a minimum of six resected lymph nodes.
  • Tumor must show negative neu proto-oncogene overexpression by FISH (Fluorescence In Situ Hybridization). Confirmation of non overexpression will be centrally assessed by authorized BCIRG (Breast Cancer International Research Group) laboratories prior to randomization.
  • Estrogen and/or progesterone receptor analysis performed on the primary tumor prior to randomization. Results must be known at the time of randomization.(Note: Patients whose tumor is estrogen receptor negative with progesterone receptor status unknown or undetermined, must have the progesterone receptor assayed in order to determine hormonal receptor status. Patients whose tumor is progesterone receptor negative with estrogen receptor status unknown or undetermined, must have the estrogen receptor assayed in order to determine hormonal receptor status).
  • Performance status index > 80%.
  • Normal cardiac function must be confirmed by (Lef Ventricular Ejection Fraction) i.e. MUGA (Multi Gated Acquisition) scan or echocardiography and within 3 months prior to registration. LVEF result must be above or equal to the lower limit of normal for the institution. The ECG results must be within normal limits or show no significant abnormalities.
  • Laboratory requirements: (within 14 days prior to registration)

    • Hematology:

      • Neutrophils > or = 2.0 x 10\^9/L
      • > or = 100 x 10\^9/L
      • > or = 10 g/dL
    • Hepatic function:

      • Total \< or = 1 UNL (Upper Normal Limit)
      • ASAT (Aspartate Amino Transferase) and ALAT (Alanine Amino Transferase) \< or = 2.5 UNL
      • Alkaline phosphatase \< or = 5 UNL
      • Patients with ASAT and/or ALAT > 1.5 x UNL associated with alkaline phosphatase > 2.5 x UNL are not eligible for the study.
    • Renal function:

      • Creatinine \< or = 175 µmol/L (2 mg/dL);
      • If limit reached, the calculated should be > or = 60mL/min.
  • Complete staging work-up within 3 months prior to registration. All patients will have contralateral mammography, chest X-ray (Posteroanterior and lateral) and/or CT scan and/or MRI (Magnetic Resonance Imaging), abdominal ultrasound and/or CT scan (computerized tomography) and/or MRI, and bone scan. In case of positive bone scan, bone X-ray is mandatory to rule out the possibility of non- hot spots. Other tests may be performed as clinically indicated.
  • Negative pregnancy test (urine or serum) within 7 days prior to registration for all women of .

Exclusion criteria

Exclusion Criteria :

  • Prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy, genetherapy , chemotherapy).
  • Prior anthracycline therapy or taxoids (paclitaxel, docetaxel) for any .
  • Prior radiation therapy for breast cancer.
  • Bilateral invasive breast cancer.
  • Pregnant, or lactating patients. Patients of must implement adequate non-hormonal measures during study treatment (chemotherapy and tamoxifen therapy) and must have negative urine or serum pregnancy test within 7 days prior to registration.
  • Any T4 or N2 or known N3 or M1 breast cancer.
  • Pre-existing motor or sensory neurotoxicity of a severity > grade 2 by NCI-CTC (National Cancer Institute - Common Toxicity Criteria), version 2.0.
  • Other serious illness or medical condition:

    • congestive heart failure or unstable angina pectoris, previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or high-risk uncontrolled arrhythmias
    • history of significant neurologic or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of
    • active uncontrolled infection
    • active peptic ulcer, unstable diabetes mellitus
  • Past or current history of neoplasm other than breast carcinoma, except for:

    • curatively treated non-melanoma skin cancer
    • carcinoma in situ of the cervix
    • other cancer curatively treated and with no evidence of disease for at least 10 years
    • ipsilateral ductal carcinoma in-situ (DCIS) of the breast
    • lobular carcinoma in-situ (LCIS) of the breast
  • Chronic treatment with unless initiated > 6 months prior to study entry and at low dose (\< 20 mg methylprednisolone or equivalent).
  • Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment should be stopped before study entry.
  • Definite for the use of corticosteroids.
  • Concurrent treatment with other experimental drugs. Participation in another clinical trial with any not marketed drug within 30 days prior to study entry.
  • Concurrent treatment with any other anti-cancer therapy.
  • Current therapy with any hormonal agent such as raloxifene, tamoxifen or other selective estrogen receptor modulators (SERMs), either for osteoporosis or prevention. Patients must have discontinued these agents prior to randomization.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,299 participants (actual)

Study arms

  • Experimental
    1

    Doxorubicin in combination with cyclophosphamide followed by docetaxel (AC -\> T)

    Drug: Docetaxel,doxorubicin, cyclophosphamide

  • Experimental
    2

    Docetaxel in combination with doxorubicin and cyclophosphamide (TAC)

    Drug: docetaxel, doxorubicin, cyclophosphamide

Interventions

  • Drugdocetaxel, doxorubicin, cyclophosphamide

    Drug pages: Docetaxel · Doxorubicin · Cyclophosphamide

    TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.

  • DrugDocetaxel,doxorubicin, cyclophosphamide

    Drug pages: Docetaxel · Doxorubicin · Cyclophosphamide

    AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.

06

What researchers measure

Primary outcomes

  1. Local, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival)

    The primary event is the local, regional or metastatic relapse or the date of second primary cancer or death from any cause (whichever occurs first). The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.

    Time frame: Median follow-up 65 months

Secondary outcomes

  1. Death From Any Cause (Overall Survival)

    The considered event is death from any cause. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.

    Time frame: Median follow-up of 65 months

07

Results

Posted Feb 17, 2010

Participant flow

Participant flow — Overall Study
MilestoneDoxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)Docetaxel + Doxorubicin and Cyclophosphamide (TAC)
Started16491649
Completed14771526
Not completed172123
Withdrew: Adverse event9761
Withdrew: Protocol violation53
Withdrew: Death21
Withdrew: Lack of efficacy74
Withdrew: Lost to follow-up35
Withdrew: Withdrawal by subject5342
Withdrew: Other57

Outcome measures

PrimaryLocal, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival)

The primary event is the local, regional or metastatic relapse or the date of second primary cancer or death from any cause (whichever occurs first). The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.

Time frame:
Median follow-up 65 months
Reported as:
Number · Participants
Local, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival)
ParticipantsDoxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)Docetaxel + Doxorubicin and Cyclophosphamide (TAC)
Local, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival)356352
Statistical analysis
  • Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) vs Docetaxel + Doxorubicin and Cyclophosphamide (TAC) · Log Rank · p = 0.978 (Cumulative incidence functions in each treatment group were calculated using non-parametric Kaplan-Meier estimates.) · Hazard ratio (hr): 1.00 · 95% CI 0.86 to 1.16
SecondaryDeath From Any Cause (Overall Survival)

The considered event is death from any cause. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.

Time frame:
Median follow-up of 65 months
Reported as:
Number · Participants
Death From Any Cause (Overall Survival)
ParticipantsDoxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)Docetaxel + Doxorubicin and Cyclophosphamide (TAC)
Death From Any Cause (Overall Survival)187 (65.64 to 65.91)202 (65.48 to 65.84)
Statistical analysis
  • Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) vs Docetaxel + Doxorubicin and Cyclophosphamide (TAC) · Log Rank · p = 0.371 (Cumulative incidences calculated in each group using non-parametric Kaplan-Meier estimates.) · Hazard ratio (hr): 0.91 · 95% CI 0.75 to 1.11

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)—331/1,634 (20.3%)1,634/1,634 (100%)
Docetaxel + Doxorubicin and Cyclophosphamide (TAC)—520/1,635 (31.8%)1,629/1,635 (99.6%)
Most frequent serious events
Showing 10 of 121
Most frequent serious events
EventDoxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)Docetaxel + Doxorubicin and Cyclophosphamide (TAC)
Fever (including serious febrile neutropenia)General disorders122/1634293/1635
Infection (including neutropenic infection)Infections and infestations86/1634143/1635
LeukopeniaBlood and lymphatic system disorders18/163456/1635
VomitingGastrointestinal disorders16/163428/1635
NauseaGastrointestinal disorders14/163419/1635
Thrombophlebitis DeepVascular disorders14/163414/1635
DiarrheaGastrointestinal disorders13/163413/1635
StomatitisGastrointestinal disorders8/16349/1635
DehydrationMetabolism and nutrition disorders8/16346/1635
Derm ExfoliatingSkin and subcutaneous tissue disorders8/16341/1635
Most frequent other events
Showing 10 of 54
Most frequent other events
EventDoxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)Docetaxel + Doxorubicin and Cyclophosphamide (TAC)
AlopeciaSkin and subcutaneous tissue disorders1601/16341587/1635
NauseaGastrointestinal disorders1435/16341334/1635
AstheniaMusculoskeletal and connective tissue disorders1328/16341310/1635
NeutropeniaBlood and lymphatic system disorders1133/16341049/1635
StomatitisGastrointestinal disorders1035/16341026/1635
VomitingGastrointestinal disorders907/1634742/1635
MyalgiaMusculoskeletal and connective tissue disorders834/1634587/1635
Nail disorderSkin and subcutaneous tissue disorders729/1634363/1635
NeuropathyNervous system disorders723/1634482/1635
AnemiaBlood and lymphatic system disorders461/1634658/1635

Baseline characteristics

Age, Customized
Age, Customized(Participants)Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)Docetaxel + Doxorubicin and Cyclophosphamide (TAC)Total
> =65 years8583168
Between 65 and 50 years7847831567
Between 49 and 35 years6897101399
< =35 years9173164
Age, Continuous
Age, Continuous(years)Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)Docetaxel + Doxorubicin and Cyclophosphamide (TAC)Total
Median50 (22 to 74)50 (24 to 72)50 (22 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)Docetaxel + Doxorubicin and Cyclophosphamide (TAC)Total
Female164916493298
Male000
Region of Enrollment
Region of Enrollment(participants)Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)Docetaxel + Doxorubicin and Cyclophosphamide (TAC)Total
Argentina313263
Australia156144300
Belgium333164
Bosnia And Herzegovina5510
Brazil192140
Bulgaria111122
Canada174180354
China211738
Colombia6814
Croatia292958
Cyprus257
Czech Republic111021
Egypt448
Estonia325
France5958117
Germany224223447
Greece538
Hong Kong369
Hungary343569
Ireland8388171
Israel6367130
Lebanon231841
Mexico538
New Zealand211940
Poland167168335
Portugal213
Russian Federation323567
Romania171936
Saudi Arabia202
Slovenia151732
South Africa192140
South Korea222749
Spain264167
Taiwan181634
United States294278572
Uruguay426
Venezuela6511
Hormonal Receptor Status
Hormonal Receptor Status(Participants)Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)Docetaxel + Doxorubicin and Cyclophosphamide (TAC)Total
Positive134813462694
Negative301303604
Karnofsky Performance Status at Baseline
Karnofsky Performance Status at Baseline(Participants)Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)Docetaxel + Doxorubicin and Cyclophosphamide (TAC)Total
80 - Activity with effort; some signs of disease363369
90 - Normal activity; minor signs of disease315323638
100 - Normal no complaints; no evidence of disease129812932591
Menopausal status
Menopausal status(Participants)Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)Docetaxel + Doxorubicin and Cyclophosphamide (TAC)Total
Pre-Menopausal or Other age < 50 Years8668631729
Post-Menopausal or Other age > 50 Years7837861569
Number of Positive Lymph Nodes
Number of Positive Lymph Nodes(Participants)Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)Docetaxel + Doxorubicin and Cyclophosphamide (TAC)Total
[0]011
[1 to 3]101010052015
[4 to 10]462456918
> 10177187364

2 further baseline measures are reported on the registry.

08

Study locations

37 sites
  • Sanofi-Aventis
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis
    Buenos Aires, Argentina
  • Sanofi-Aventis
    Macquarie Park, Australia
  • Sanofi-Aventis
    Brussels, Belgium
  • Sanofi-Aventis
    Sarajevo, Bosnia and Herzegovina
  • Sanofi-Aventis
    Sao Paulo, Brazil
  • Sanofi-Aventis
    Sofia, Bulgaria
  • Sanofi-Aventis
    Laval, Canada
  • Sanofi-Aventis
    Shanghai, China
  • Sanofi-Aventis
    Bogota, Colombia
  • Sanofi-Aventis
    Zagreb, Croatia
  • Sanofi-Aventis
    Nikosia, Cyprus
  • Sanofi-Aventis
    Praha, Czech Republic
  • Sanofi-Aventis
    Cairo, Egypt
  • Sanofi-Aventis
    Tallin, Estonia
  • Sanofi-Aventis
    Paris, France
  • Sanofi-Aventis
    Berlin, Germany
  • Sanofi-Aventis
    Kallithea, Greece
  • Sanofi-Aventis
    Hong Kong, Hong Kong
  • Sanofi-Aventis
    Budapest, Hungary
  • Sanofi-Aventis
    Dublin, Ireland
  • Sanofi-Aventis
    Natanya, Israel
  • Sanofi-Aventis
    Seoul, Korea, Republic of
  • Sanofi-Aventis
    Beirut, Lebanon
  • Sanofi-Aventis
    Mexico, Mexico
  • Sanofi-aventis
    Auckland, New Zealand
  • Sanofi-Aventis
    Warsaw, Poland
  • Sanofi-Aventis
    Porto Salvo, Portugal
  • Sanofi-Aventis
    Bucuresti, Romania
  • Sanofi-Aventis
    Moscow, Russian Federation
  • Sanofi-Aventis
    Jeddah, Saudi Arabia
  • Sanofi-Aventis
    Ljubljana, Slovenia
  • Sanofi-Aventis
    Midrand, South Africa
  • Sanofi-Aventis
    Barcelona, Spain
  • Sanofi-Aventis
    Taipei, Taiwan
  • Sanofi-Aventis
    Montevideo, Uruguay
  • Sanofi-Aventis
    Caracas, Venezuela
09

References and documents

Publications

  • Press MF, Sauter G, Buyse M, Fourmanoir H, Quinaux E, Tsao-Wei DD, Eiermann W, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Mackey JR, Bee V, Ma Y, Villalobos I, Campeau A, Mirlacher M, Lindsay MA, Slamon DJ. HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. J Clin Oncol. 2016 Oct 10;34(29):3518-3528. doi: 10.1200/JCO.2016.66.6693. PubMed 27573653 ↗
  • Mackey JR, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press MF, Sauter G, Lindsay M, Houe V, Buyse M, Drevot P, Hitier S, Bensfia S, Eiermann W. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. Ann Oncol. 2016 Jun;27(6):1041-1047. doi: 10.1093/annonc/mdw098. Epub 2016 Mar 2. PubMed 26940688 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2001, a primary completion of Oct 2008 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2006
First posted
Apr 7, 2006
Start
Nov 2001
Primary completionActual
Oct 2008
CompletionActual
Oct 2013
Results first posted
Feb 17, 2010
Last update
Dec 30, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00312208
Lead sponsor
Sanofi
Collaborators
Cancer International Research Group (CIRG)
Responsible party
Sponsor
First posted
Apr 7, 2006
Start date
Nov 2001
Primary completion
Oct 2008
Completion
Oct 2013
Results posted
Feb 17, 2010
Last update
Dec 30, 2013

Study contacts

Jean-Philippe AUSSEL
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Doxorubicin · Cyclophosphamide

Start the discussion